Curis FY26 Q2 net loss widens 71% to $32.78 million vs FY25; revenue posts no revenue vs FY25
CRIS•Curis reports Q2 results and liquidity update
- Curis posted a GAAP net loss of $8.58 million for the quarter ended June 30, 2026, essentially unchanged year over year.
- Revenue fell to no revenue from $2.75 million a year earlier after the November 2025 sale of Erivedge ended royalty entitlement.
- Research and development expense slipped 10% to $6.71 million; general and administrative costs eased 9% to $3.23 million.
- Other income swung to $1.36 million from an expense of $342,000, driven by warrant liability fair-value changes tied to the January 2026 PIPE.
- Cash and cash equivalents totaled $5.1 million at June 30; an August 2026 offering added about $4.8 million, funding operations into Q4 2026.
Related News
HIVE turns to Q1 FY27 net loss of $142.91 million; revenue rises 73.48% to $79.12 million vs Q1 FY26
HIVE•
Equus Total Return Q2 net investment loss widens to $0.9 million; investment income holds at $0.3 million
EQS•
